Xbrane Biopharma AB (publ) (XBRANE.ST)
- Previous Close
0.2165 - Open
0.2275 - Bid 0.2160 x --
- Ask 0.2180 x --
- Day's Range
0.2130 - 0.2275 - 52 Week Range
0.1544 - 93.2000 - Volume
11,591,005 - Avg. Volume
22,632,784 - Market Cap (intraday)
326.544M - Beta (5Y Monthly) 1.04
- PE Ratio (TTM)
-- - EPS (TTM)
-1.2700 - Earnings Date May 16, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
1.43
Xbrane Biopharma AB (publ), a biotechnology company, develops, manufactures, and sells biosimilars. The company is developing Ximluci, a ranibizumab biosimilar used for the treatment of wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, retinal vein occlusion, and visual impairment due to cordial neovascularization in adults. Its pre-clinical phase products include BIIB801, a biosimilar candidate for the treatment of rheumatoid arthritis, psoriasis, Crohn's disease, and axial spondylitis; Xdivane for skin cancer, lung cancer, renal cell cancer, head and neck cancer, and bladder and urinary tract cancer; Xtrudane for brain cancer, melanoma, lung cancer, kidney cell cancer, head and neck cancer, and bladder and urinary tract cancer; and Xdarzane for multiple melanoma. Xbrane Biopharma AB (publ) was incorporated in 2008 and is headquartered in Solna, Sweden.
www.xbrane.comRelated News
Performance Overview: XBRANE.ST
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: XBRANE.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: XBRANE.ST
Valuation Measures
Market Cap
326.54M
Enterprise Value
492.62M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.23
Price/Book (mrq)
1.91
Enterprise Value/Revenue
2.06
Enterprise Value/EBITDA
-1.62
Financial Highlights
Profitability and Income Statement
Profit Margin
-162.60%
Return on Assets (ttm)
-27.60%
Return on Equity (ttm)
-108.02%
Revenue (ttm)
238.73M
Net Income Avi to Common (ttm)
-322.03M
Diluted EPS (ttm)
-1.2700
Balance Sheet and Cash Flow
Total Cash (mrq)
65.4M
Total Debt/Equity (mrq)
135.10%
Levered Free Cash Flow (ttm)
-244M
Research Analysis: XBRANE.ST
Company Insights: XBRANE.ST
XBRANE.ST does not have Company Insights